http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180013824-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff283c7d6797987f01db547f606e6b32 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate | 2017-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc03cc6d8eace30459b32e5831ac143f |
publicationDate | 2018-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-20180013824-A |
titleOfInvention | The diagnosis biomarker for predicting the emergence of castration-resistance in prostate cancer and the therapeutic composition for suppressing castration-resistance in the castration-resistant prostate cancer |
abstract | The present invention relates to a diagnostic biomarker composition for predicting the incidence of hormone refractory disease in prostate cancer and a composition for delaying or preventing the occurrence of hormone refractory disease in high-grade prostate cancer or inhibiting hormone refusal in hormone-refractory prostate cancer. The present invention is a composition for treating prostate cancer comprising shRNA or siRNA corresponding to the ccm1 gene to inhibit expression of CCM1 protein. The present invention also provides a composition for treating prostate cancer, which comprises DDX5 protein as an active ingredient. According to the present invention, a composition that can be used as a diagnostic biomarker capable of predicting the occurrence of hormone refractory can be provided. |
priorityDate | 2017-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 205.